Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC).
Document type:
Meeting Abstract
Author(s):
de Wit, M; Harbeck, N; Thomssen, C; Becker, K; Psonka, A; Hoffmann, R; Villena, C; Schutte, M; Hossfeld, DK